Cannabis Drug Interactions: Pharmacology Science Guide

Pharmacokinetic Interactions: CYP Enzyme Inhibition

CBD is a potent inhibitor of multiple cytochrome P450 enzymes, with the most clinically significant being CYP3A4, CYP2C9, CYP2C19, and CYP2D6. CYP3A4 metabolizes approximately 50% of all pharmaceutical drugs, making CBD-mediated CYP3A4 inhibition potentially relevant to a broad range of co-administered medications. Inhibition of CYP3A4 by CBD increases plasma concentrations of substrates including statins (atorvastatin, simvastatin), calcium channel blockers, benzodiazepines, opioids, and immunosuppressants.

The clobazam-CBD interaction is the most clinically characterized, emerging from Epidiolex (CBD) development for pediatric epilepsy. CBD significantly inhibits CYP2C19 and possibly CYP3A4, leading to elevated plasma levels of clobazam active metabolite N-desmethylclobazam in children receiving both drugs. This interaction requires clobazam dose reduction in some patients but also contributes to enhanced seizure control — a complex interaction where the metabolic interaction has therapeutic consequences.

Warfarin, a narrow therapeutic index anticoagulant metabolized by CYP2C9, represents perhaps the highest-risk CBD interaction. Multiple case reports document INR (international normalized ratio) elevation and bleeding risk in warfarin patients initiating CBD. This interaction is clinically significant at CBD doses commonly used by patients (150-600mg/day). All patients taking warfarin or other anticoagulants should have INR monitored if initiating cannabinoid use, as detailed in the general cannabis pharmacokinetics overview.

THC Pharmacokinetic Interactions

THC also participates in CYP enzyme interactions, though its lower typical dose compared to therapeutic CBD limits clinical significance for most interactions. THC inhibits CYP3A4 at concentrations achieved with heavy use, potentially elevating levels of CYP3A4 substrates including tacrolimus (immunosuppressant), fentanyl, and oxycodone. Cases of tacrolimus toxicity in transplant patients using cannabis have been reported.

THC is metabolized by CYP2C9 and CYP3A4; inhibitors of these enzymes (ketoconazole, fluconazole, certain HIV protease inhibitors) can significantly elevate THC plasma levels and prolong psychoactive effects and adverse effects. This is clinically relevant for HIV patients using both cannabis and antiretroviral therapy, as some protease inhibitors are potent CYP3A4 inhibitors.

The P-glycoprotein (P-gp) transporter, which limits drug absorption and CNS penetration, is also a THC interaction target. THC inhibits P-gp, potentially increasing CNS penetration and toxicity of P-gp substrate drugs including digoxin, vinblastine, and certain antifungals. These pharmacokinetic complexities underscore the importance of medication review before initiating cannabis in patients with polypharmacy, especially when cardiac medications are involved.

Pharmacodynamic Interactions: CNS Depression

The most practically important pharmacodynamic cannabis interactions involve additive CNS depression with centrally acting medications. Cannabis (primarily THC) produces sedation, psychomotor impairment, and cognitive slowing that is additive with other CNS depressants: opioids, benzodiazepines, alcohol, antihistamines, muscle relaxants, and antiepileptic drugs with sedative profiles.

The opioid-cannabis interaction is bidirectional and complex: at the pharmacodynamic level, cannabis adds sedation and respiratory depression risk to opioid regimens. At analgesic circuits, cannabis and opioids may synergistically reduce pain, potentially allowing opioid dose reduction. This dual nature — interaction risk and potential dose-sparing benefit — requires careful monitoring rather than categorical avoidance.

Alcohol-cannabis interaction produces greater cognitive impairment than either alone, with particular impact on driving performance. Studies demonstrate that alcohol and cannabis co-consumption produces driving impairment exceeding either substance alone, a critical public safety consideration as legalization increases concurrent use prevalence. THC and alcohol also produce additive cardiovascular stress (tachycardia, blood pressure variation) relevant to the cardiovascular risk profile.

Clinically Significant Interactions: Quick Reference

High-risk cannabis drug interactions requiring active monitoring: 1) Warfarin/anticoagulants (INR elevation via CYP2C9 inhibition — weekly INR monitoring recommended for 2-4 weeks after cannabis initiation); 2) Clobazam/antiepileptics (active metabolite elevation — dose adjustment may be needed); 3) Tacrolimus/cyclosporine (toxicity risk — immunosuppressant levels must be monitored); 4) Opioids (additive CNS/respiratory depression — use minimum effective dose combination); 5) Benzodiazepines (additive sedation — consider dose reduction).

Moderate-risk interactions warranting awareness: statins (elevated muscle toxicity risk from statin level increases), calcium channel blockers, HIV antiretrovirals (bidirectional interactions), antidepressants/antipsychotics (complex interactions via multiple CYP pathways), and metformin (possible glucose metabolism interaction via ECS metabolic effects).

Medication review by a pharmacist or physician before initiating cannabis is strongly recommended for patients on more than 2 prescription medications, particularly narrow-therapeutic-index drugs. As medical cannabis use expands, interaction databases are being developed but remain incomplete given limited clinical pharmacology data for most cannabinoid-drug pairs. Ongoing pharmacokinetic research in cannabis clinical trials is building this evidence base systematically.